Cantor Fitzgerald analyst Olivia Brayer lowered the firm’s price target on Bristol Myers to $52 from $55 and keeps a Neutral rating on the shares. The firm, which made slight adjustments to all of its large-cap biotechnology models ahead of Q1 earnings season for the group, lowered its target for Bristol given a more-modest growth ramp for new products. The “usual seasonal headwinds that typically make this one of the weaker quarters for the industry,” the analyst added in the preview note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BMY:
- Options Volatility and Implied Earnings Moves This Week, April 22 – April 26, 2024
- Bristol Myers price target raised to $52 from $51 at Wells Fargo
- Bristol Myers: Krazati plus cetuximab showed ORR of 34%, PFS of 6.9 months
- Bristol Myers presents new data from Phase 3 EMERGENT program evaluating KarXT
- Bristol Myers presents new interim long-term efficacy data from EMERGENT-4 trial
